Recruiting PHASE4 INTERVENTIONAL 2-arm NCT07125417

Non-antithrombotic Versus. Single Antiplatelet Therapy Following Left Atrial Appendage Closure

Non-Antithrombotic Versus. Single antiPlatelet Therapy Following Left Atrial Appendage Closure：NAPT-LAAC Randomized Controlled Trial

Sponsor: Boston Scientific Corporation

Conditions Aspirin High Bleeding Risk Left Atrial Appendage Closure Non-Antithrombotic Therapy Nonvalvular Atrial Fibrillation

Interventions Non-Antithrombotic Therapy Single Antiplatelet Therapy or No Therapy (Control)

Updated 1 time since 2025 Last updated: Aug 12, 2025 Started: May 29, 2025 Primary completion: May 31, 2029 Completion: Mar 31, 2030

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Aspirin and High Bleeding Risk and is currently actively recruiting participants. Boston Scientific Corporation leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

1 version recorded

Recruiting — PHASE4 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boston Scientific Corporation
OCEAN-SHD Study Group

Data source: OCEAN-SHD Study Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bunkyo-ku, Japan , Chiyoda-ku, Japan , Fuchū, Japan , Gifu, Japan , Isehara, Japan , Itabashi-ku, Japan , Katsushika-ku, Japan , Kawasaki, Japan , Kitakyushu, Japan , Kurashiki, Japan and 10 more locations